Aclaris Therapeutics (ACRS) vs Allogene Therapeutics (ALLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 84.8% versus a gain of 5.9%. Over five years, ACRS leads with a -79.8% price change compared with -91.3% for ALLO. Aclaris Therapeutics is the larger company by market cap ($500.5 million vs $494.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | ALLO |
|---|---|---|
| Share price | $3.40 | $1.43 |
| Market cap | $500.48M | $494.05M |
| 1-day change | -8.11% | -2.05% |
| YTD return | +12.96% | +4.38% |
| 1-year return | +84.78% | +5.93% |
| 5-year return | -79.77% | -91.32% |
| EPS (TTM) | $-0.58 | $-0.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $4.46 |
| 52-week low | $1.74 | $1.04 |
| Distance from 52-week high | -48.48% | -67.94% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +199.41% | +529.37% |
| Average volume | 2.38M | 5.78M |
| Shares outstanding | 147.20M | 345.49M |
| Employees | 69 | 150 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed ALLO by 78.9 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
ACRS vs ALLO FAQ
Which is bigger, Aclaris Therapeutics or Allogene Therapeutics?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $500.48M compared with $494.05M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ACRS or ALLO?
ACRS returned +84.78% over the past 12 months, compared with +5.93% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Allogene Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aclaris Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Allogene Therapeutics.